相关实验视频

Updated: Jan 16, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

长期使用质子抑制剂与低风险的胃神经内分泌瘤之间的关联

Taymeyah Al-Toubah¹, Eleonora Pelle¹, Mintallah Haider¹

¹Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Annals of surgical oncology

|October 1, 2025

概括

长期使用质子抑制剂 (PPI) 可能与不太具有攻击性的胃神经内分泌瘤 (NETs) 有关. 这表明PPI相关NET的潜在新分类 (类型4),与零星类型不同.

科学领域:

胃肠病学胃肠病学
在瘤学瘤学.
内分泌学在内分泌学.

背景情况:

胃神经内分泌瘤 (NETs) 很少见,其中1型和2型与高胃血症有关,而3型则偶尔和积极地发生.
长期使用质子抑制剂 (PPI) 会导致胃高血症,但与PPI相关的胃NET很少被报告,缺乏明确的分类.

研究的目的:

研究长期使用PPI病史的患者胃NET的特征和结果.
为了确定PPI使用是否影响胃NET的攻击性和转移潜力.

主要方法:

在H.李莫菲特癌症中心 (2008年1月至2023年8月) 胃NET病例的回顾性分析.
排除1型,2型胃 NET 和差异化神经内分泌癌.
收集关于PPI使用,胃素水平,瘤等级和偶发性胃NET的疾病阶段的数据.

主要成果:

在90名符合条件的患者中,50%的患者长期使用PPI (≥5年).
研究中的所有瘤都差异化得很好 (等级1-3).
长期使用PPI的患者没有远程转移性疾病 (0%),而没有长期使用PPI的患者有62% (p < 0.0001).

结论:

长期使用PPI的患者的胃NET似乎比零星类型更不具侵略性.
对于与PPI相关的病例,提出了一种新的分类,即"4型"胃 NET.
这种拟议的4型胃NET的预后更类似于1型而不是3型.

关键词:

癌类动物的癌类动物.胃部胃部胃部神经内分泌的神经内分泌神经内分泌瘤是一个神经内分泌瘤.质子抑制剂质子抑制剂

更多相关视频

Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa

Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa

Published on: September 27, 2018

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

相关概念视频

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...